Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Go back to Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension| (NASDAQ: TBPH) | Delayed: 16.64 +0.15 (0.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.49 | 52 Week High | $38.92 | |||
| Open | $16.42 | 52 Week Low | $12.87 | |||
| Day High | $16.67 | P/E | N/A | |||
| Day Low | $16.42 | EPS | $0.00 | |||
| Volume | 230,170 | |||||
